Can You Have a Bile Duct Stone with Normal Bloodwork?
Yes, common bile duct (CBD) stones can absolutely be present despite completely normal laboratory tests, though this occurs in only about 5% of cases. The British Society of Gastroenterology explicitly states that "normal results do not preclude further investigation if clinical suspicion remains high" 1.
The Reality of Normal Labs with CBD Stones
While uncommon, normal liver function tests do not rule out choledocholithiasis. Research demonstrates that 5.4% of patients with confirmed CBD stones had consistently normal liver chemistry tests 2. This is a critical pitfall—clinicians must not be falsely reassured by normal bloodwork when clinical suspicion is high.
Patients most likely to have CBD stones despite normal labs include:
- Older patients (>55 years)
- Those presenting with abdominal pain 2
Typical Bloodwork Abnormalities in CBD Stones
The standard initial workup consists of liver function tests (LFTs), which typically show 1:
Most Sensitive Markers:
- Gamma-glutamyl transferase (GGT): Most powerful predictor with 97.9% negative predictive value and 87.5% sensitivity 3
- Alkaline phosphatase: High sensitivity when elevated
- Total bilirubin: Highest specificity (87.5%) among biochemical markers 3
Additional Markers:
- Alanine aminotransferase (ALT)
- Aspartate aminotransferase (AST)
Clinical Context Matters:
- Bilirubin >4 mg/dL combined with dilated CBD on imaging is a "very strong predictor" per guidelines 1
- Bilirubin 1.8-4.0 mg/dL is considered a "strong predictor" 4
- Having at least one abnormal elevation among the five biochemical parameters shows 87.5% sensitivity 3
Critical Clinical Algorithm
When labs are normal but clinical suspicion persists:
Do not stop at normal LFTs and ultrasound—this combination has a 99.5% negative predictive value, but that still leaves 0.5% with stones 5
Proceed to advanced imaging (MRCP or EUS) if:
- Patient has typical biliary pain
- Age >55 years
- History of gallstones with new symptoms
- Clinical features suggesting cholangitis 1
Risk stratification approach 1:
- Low likelihood (normal results): Consider alternative diagnosis but don't dismiss if symptoms persist
- Intermediate likelihood: CBD dilatation with normal LFTs OR abnormal LFTs with normal caliber biliary system—requires MRCP or EUS
- High likelihood: Stone visualized on ultrasound, cholangitis features, or pain + duct dilatation + jaundice
Important Caveats
The major pitfall: Relying solely on ultrasound impression of CBD stones without ductal dilatation is unreliable—it does not predict CBD stones (OR 0.97) 5. Ultrasound sensitivity for CBD stones ranges widely from 32% to 100%, with summary sensitivity of only 73% 6.
Biochemical tests have high negative predictive values (94.7-97.9%) but are not perfect 3. When all five biochemical markers are normal AND ultrasound shows normal CBD diameter, the likelihood of CBD stones is very low but not zero 5.
Recent evidence shows that patients meeting high-risk criteria based only on clinical predictors (cholangitis or bilirubin >4 mg/dL with dilated CBD) without imaging evidence of stones have only a 50-55% stone detection rate at ERCP 7. This underscores that even "high-risk" clinical criteria without imaging confirmation can lead to unnecessary invasive procedures.
Practical Recommendation
For patients with persistent symptoms suggestive of CBD stones but normal bloodwork: Obtain transabdominal ultrasound first, then proceed to MRCP or EUS based on clinical suspicion rather than dismissing the diagnosis based on normal labs alone 1. The combination of clinical judgment, imaging, and biochemistry—not any single test—determines the need for therapeutic intervention.